The Rixa Difference: Why Most GLP-1 Programs Fail PCOS Patients Let's be blunt: the way most telehealth companies handle GLP-1 prescriptions is failing women with PCOS
Factors influencing long-term continuation include the degree of weight loss achieved, improvement in obesity-related comorbidities, side effect profile, cost considerations, and patient preference
Retrieved from Ko, K
1 To understand whether non-diabetic patients prescribed GLP-1 medications experience similar rates of these gastrointestinal (GI) side effects, we studied 367,439 non-diabetic patients, including 170,842 who were on a GLP-1 medication and 196,597 who were on other weight loss medications
A properly reconstituted semaglutide solution is clear, colorless, and free of particles
A significant milestone to bring in the new year, the FDA approved Wegovy (semaglutide) on Dec